Romania approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 29, 2014 – Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Earlier this month, Sandoz also received marketing authorizations for AirFluSal® Forspiro® in Germany, Sweden and Hungary. …

/by

Romania approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 29, 2014 – Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Earlier this month, Sandoz also received marketing authorizations for AirFluSal® Forspiro® in Germany, Sweden and Hungary. …

/by

Novartis announces Q4/Full Year 2013 results

Basel, January 29, 2014 – Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects.

Read the media release

…
/by

Novartis recognized among world’s most sustainable companies in Corporate Knights Global 100

Basel, January 27, 2014 – Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100.

Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index today at the World Economic Forum in Davos.

“Our inclusion in the Global 100 list is a testimony to our longstanding commitment to corporate responsibility,” said Joseph Jimenez, CEO of Novartis. “Being recognized among the top 100 sustainability performers in the world underscores that doing business responsibly …

/by

Sandoz launches Airflusal ® Forspiro® in Denmark

Copenhagen, January 20, 2014 – Sandoz announces that it is launching in Denmark today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received earlier this week also in Germany and Sweden.

Today’s launch in Denmark follows the announcement on December 18 that Sandoz had received its first EU market authorization for AirFluSal® Forspiro® after the completion the EU regulatory …

/by

Sweden approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 14, 2014 – Sandoz announced today it has received Swedish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device. On January 13, 2014 Sandoz also received marketing authorization for AirFluSal® Forspiro® in Germany.

Sweden has approved the …

/by

Germany approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 13, 2014 – Sandoz announced today it has received German marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Germany has approved the 50-500 µg dosage form for the continuous treatment of patients above 12 years of age with persistent …

/by

Novartis publishes Corporate Responsibility Overview

Januar 08, 2014 – Novartis recently published a comprehensive overview of its Corporate Responsibility strategy and programs.

Learn more (PDF 743 KB)

/by

Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee

  • Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US
  • Biosimilar filgrastim recommended to be approved for use in all requested indications
  • Committee’s recommendation based on review of extensive data from analytical, non-clinical, clinical studies and post-marketing pharmacovigilance

Holzkirchen, January 7, 2014 – Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its …

/by

Sandoz receives first approval for Airflusal® Forspiro®

Munich, December 18, 2013 – Sandoz announced today that it has received Danish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The Danish approval follows the completion of EU decentralized procedures (DCP) for eight EU countries, including Denmark.

  • Novel inhaler approved for patients with asthma and COPD
  • Approval follows completion of EU decentralized procedure (DCP)
  • AirFluSal® Forspiro® strengthens Sandoz respiratory portfolio and …
/by